Business
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral pre
About this update from Camp4 Therapeutics Corporation
[{"type":"image","alt":"CAMP4 Therapeutics","displaySize":"","headline":null,"caption":"CAMP4 Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/21702dc1d4660b70780cbc865b3cc20b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FOgCfQCojUOWCCToPToW_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/21702dc1d4660b70780cbc865b3cc20b","width":300,"height":94}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotes","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Nominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-001 in healthy volunteers","length":282,"tagName":"p"}]},{"val":[{"type":"text","content":"Expect to receive milestone payment from Fulcrum Therapeutics under the license agreement signed July 2023 for our Diamond-Blackfan Anemia (DBA) program","length":152,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":876,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":457,"tagName":"p"},{"type":"text","content":"“We are very pleased with the strong ...